The FDA granted breakthrough therapy designation to an experimental drug from Amgen for patients with FGFR2b over expressing and HER2-negative gastric cancer.
Adding Herceptin to chemotherapy improved outcomes for patients with HER2-positive advanced gastric cancer in a clinical trial.
Enhertu from Daiichi-Sankyo is now approved in Japan for the treatment of HER2-positive gastric cancer.
Pieris and Eli Lilly have partnered to test a combination of Cyramza, paclitaxel and Pieris’ novel bispecific antibody in HER2-positive gastric cancer.
People with HER2-positive gastric cancer should not take proton pump inhibitors for heartburn while they are undergoing treatment, recent studies have found.